AUTRATA, Rudolf, Inka KREJČÍŘOVÁ, Kateřina ŠENKOVÁ, Marie HOLOUŠOVÁ, Zdeněk DOLEŽEL and Ivo BOREK. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology. Milano, Italy, 2012, vol. 22, No 5, p. 687-694. ISSN 1120-6721. doi:10.5301/ejo.5000166.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II
Authors AUTRATA, Rudolf (203 Czech Republic, guarantor, belonging to the institution), Inka KREJČÍŘOVÁ (203 Czech Republic, belonging to the institution), Kateřina ŠENKOVÁ (203 Czech Republic, belonging to the institution), Marie HOLOUŠOVÁ (203 Czech Republic), Zdeněk DOLEŽEL (203 Czech Republic, belonging to the institution) and Ivo BOREK (203 Czech Republic, belonging to the institution).
Edition European Journal of Ophthalmology, Milano, Italy, 2012, 1120-6721.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.912
RIV identification code RIV/00216224:14110/12:00060678
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5301/ejo.5000166
UT WoS 000310177100002
Keywords in English Anti-VEGF; Pegaptanib (Macugen); RetCam photography; Retinopathy of prematurity; Stage 3+; Zone I
Tags International impact
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 22. 4. 2013 15:25.
Abstract
To investigate efficacy of intravitreal injection of pegaptanib and laser photocoagulation for treatment of stage 3+ retinopathy of prematurity (ROP) affecting zone I and posterior zone II, and to compare the results in terms of regression, development of peripheral retinal vessels, and final structural outcome with conventional laser photocoagulation or combined with cryotherapy. Methods. In a prospective comparative study, 152 eyes with zone I, II posterior ROP 3+ (76 premature rabies), from 2009 to 2011, were included. Patients were randomly assigned to receive intravitreal pegaptanib (Macugen 0.3 mg = 0.02 mL, Pfizer) with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants) or only laser therapy combined with cryotherapy in group 2 (84 eyes of 42 infants), bilaterally. The primary outcome of treatment success was defined as absence of recurrence of stage 3+ ROP. The mean follow-up after treatment was 19.3 months in group 1 and 21.5 months in group 2. Results. Final favorable anatomic outcome and stable regression of ROP at last control examination was noted in 89.7% of eyes in group 1 and 60.8 % of eyes in group 2. Regression of plus disease and peripheral retinal vessels development appeared significantly more rapidly in group 1. No recurrence of neovascularization (stage 3+ ROP) was identified in 85.4% of patients in group 1 and 50% of patients in group 2. Conclusions. Results of this study support the administration of intravitreal pegaptanib as useful therapy in the management of stage 3+ ROP.
PrintDisplayed: 7. 12. 2022 08:41